Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2217/pgs.10.34 http://scihub22266oqcxt.onion/10.2217/pgs.10.34 C4867543!4867543!20350127     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20350127&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacogenomics 2010 ; 11 (4): 487-91 Nephropedia Template TP {{tp|p=20350127|t=2010. Pharmacogenomics of antihypertensive drugs: past, present and future |pdf=|usr=}}{{20350127}} gab.com Text Pharmacogenomics of antihypertensive drugs: past, present and future JO: Pharmacogenomics http://www.kidney.de/pget.php?&tw=1&pmid=20350127 #FOAvip Hypertension pharmacogenomics holds the promise of leading to individualized drug treatment approaches for the approximately 1 billion individuals worldwide with hypertension. Prior to 2000, the literature on hypertension pharmacogenomics was quite limited. The last decade has seen a substantial growth in the literature, with several examples of genes that appear to play an important role in antihypertensive response. The last decade has also made apparent the numerous challenges in hypertension pharmacogenomics, and addressing those challenges will be important. Moving forward, it seems clear that collaboration among researchers to allow replication or joint analyses will be essential in advancing the field, as will the use of genome-wide association approaches. The next decade should clearly define the clinical potential for hypertension pharmacogenomics. Twit Text FOAVip Pharmacogenomics of antihypertensive drugs: past, present and future ????Pharmacogenomics http://www.kidney.de/pget.php?&tw=1&pmid=20350127 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=20350127 #FOAvip English Wikipedia <ref>{{Cite pmid|20350127}}</ref> Pharmacogenomics of antihypertensive drugs: past, present and future #MMPMID20350127 Johnson JA Pharmacogenomics 2010[Apr]; 11 (4): 487-91 PMID20350127show ga Hypertension pharmacogenomics holds the promise of leading to individualized drug treatment approaches for the approximately 1 billion individuals worldwide with hypertension. Prior to 2000, the literature on hypertension pharmacogenomics was quite limited. The last decade has seen a substantial growth in the literature, with several examples of genes that appear to play an important role in antihypertensive response. The last decade has also made apparent the numerous challenges in hypertension pharmacogenomics, and addressing those challenges will be important. Moving forward, it seems clear that collaboration among researchers to allow replication or joint analyses will be essential in advancing the field, as will the use of genome-wide association approaches. The next decade should clearly define the clinical potential for hypertension pharmacogenomics. äPharmacogenomics of antihypertensive drugs: past, present and future (epmc).pdf DeepDyve Pubget Overpricing